- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03010410
Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS)
Aging is associated with immunosenescence and impaired host defense mechanisms, contributing to influenza-related morbidity and mortality. Preliminary data demonstrate that the platelet transcriptome is markedly different between healthy subjects and influenza patients. Interferon-induced transmembrane proteins (IFITM) family members are among the transcripts significantly increased in platelets during influenza and expression of IFITM-3 is impaired in elderly subjects, a pattern associated with increased mortality. This study will build on these data and investigate if aging influences the expression of platelet IFITM family members in patients with influenza and sepsis.
This study will prospectively determine if aging alters the induction of (IFITMs) in platelets from hospitalized influenza and sepsis patients. The study will also determine if diminished expression of IFITM family members correlates with an increased risk of adverse outcomes in older influenza and sepsis patients.
Studienübersicht
Detaillierte Beschreibung
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
Utah
-
Murray, Utah, Vereinigte Staaten, 84107
- Intermountain Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- ≥18 years old at the time of enrollment
- Meet one of the following three main criteria:
A. INFLUENZA (AND OTHER RESPIRATORY VIRUS) PATIENTS:
Patients admitted to the intensive care unit (ICU) with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses within 1 week of symptom onset. Influenza or other respiratory virus will be diagnosed using an RT-PCR viral panel on a respiratory tract specimen, as is currently standard of care on patients admitted to the ICUs at IMC with respiratory symptoms.
OR
B. SEPSIS PATIENTS:
Sepsis patients must have
Suspected or confirmed infection
AND
- Organ dysfunction as defined by a SOFA >= 2 above baseline (if no baseline data available, SOFA assumed to be 0)
OR
C. SEPTIC SHOCK PATIENTS:
AFTER INFUSION OF 20ML/KG CRYSTALLOID OR EQUIVALENT, Septic shock patients must have
Suspected or confirmed infection
AND
Lactate > 2 mmol/L
AND
Receiving vasopressors
- All patients must be enrolled into the study within 72 hours of ICU admission
Exclusion criteria
- Have a congenital or acquired immunodeficiency disorder (e.g., chronic variable immune deficiency, agammaglobulinemia, hypogammaglobulinemia, leukocyte adhesion defects, IgA deficiency, etc.)
- Have neutropenia (<1,000/mm3)
- Have received immunosuppressant medications within the previous 30 days (e.g., prednisone or prednisone equivalent at a dose≥10mg daily for ≥14 days or any cyclosporine, TNF-alpha antagonists, tacrolimus, sirolimus, interferons, mycophenolate, biological agents, methotrexate, azathioprine, polyclonal/monoclonal antibodies, etc.)
- Have any history of bone marrow or organ transplantation
- Have an active malignancy (not including non-melanoma skin cancer or localized prostate cancer), or have received chemotherapy drugs within the last 6 months.
- Have been admitted to the ICU for greater than 72 hours
- Have a Hemoglobin level <7gm/dl
- Have clinically significant bleeding
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Influenza/respiratory virus pts <65 yrs
Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
|
|
Influenza/respiratory virus pts ≥ 65 yrs
Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
|
|
Sepsis/septic shock patients < 65 yrs
Sepsis and septic shock patients
|
|
Sepsis/septic shock patients ≥ 65 yrs
sepsis and septic shock patients
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
90 day mortality
Zeitfenster: 90 days
|
For the increased risk of mortality outcome, 90-day mortality will be the primary outcome variable.
This will be modeled using mixed effects logistic regression, using days 0, 3, and 7 as repeated measurements.
In this fashion, IFITM-3 and mortality are time-varying.
A separate model will be fitted for the younger and older groups, since age group is expected to be collinear with IFITM-3 protein.
|
90 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
28 day mortality
Zeitfenster: 28 days
|
The same sample of influenza patients will be used for mortality analysis.
Based on published and unpublished data, 28-day mortality in critically-ill influenza patients admitted to ICUs ranges from 10-40%, even during non-pandemic periods.
Based on these estimates, our sample size (n=75 younger and n=75 older) provides 84% power (two-sided alpha 0.05 comparison) to detect a difference in incidence of 29% and 9%, which is a conservative estimate of the difference between the younger and older groups.
|
28 days
|
|
Interferon-induced transmembrane protein expression in platelets
Zeitfenster: 24(±12) hours of diagnosis (day 0 or 1), day 3, 5, and 90
|
Recent evidence also demonstrates that IFITM-3 acts as a membrane organizer by facilitating clathrin-mediated endocytosis (CME).
This membrane-organizing process allows cells to internalize molecules and viruses.
CME regulates platelet membrane organization.
IFITM-3 is demonstrated as necessary for host defenses against influenza virus.
Moreover, with absent or reduced levels of IFITM-3, cells do not effectively restrict viral replication, an impaired response that may influence adverse clinical outcomes.
|
24(±12) hours of diagnosis (day 0 or 1), day 3, 5, and 90
|
|
IFITM-3 mRNA
Zeitfenster: 24(±12) hours of diagnosis (day 0 or 1), day 3, 5, and 90.
|
Platelet IFITM-3 protein levels have been seen to be increased in influenza patients and correlated with IFITM-3 mRNA (r2=0.33, p<0.005). However, in hospitalized influenza patients, platelet IFITM-3 mRNA and protein expression was decreased in older, compared to young patients. It is hypothesized that influenza will induce expression of IFITM family members in platelets; IFITM's expression will be reduced in older compared to young influenza patients. This hypothesis will be tested to determine whether or not influenza induces IFITM-3 expression in human platelets and compare older and young subjects. Here, an outcome of IFITM-3 protein will be tracked in conjunction with mRNA. |
24(±12) hours of diagnosis (day 0 or 1), day 3, 5, and 90.
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Samuel M Brown, MD MS, Intermountain Health Care, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1040298
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Sepsis
-
University of California, San FranciscoNational Cancer Institute (NCI)RekrutierungSepsis | Sepsis, schwer | Sepsis und septischer Schock | Sepsis auf der Intensivstation | Sepsis, septischer Schock | Sepsis, schwere Sepsis und septischer Schock | Sepsis mit multipler Organdysfunktion (MOD) | Sepsis mit akuter OrgandysfunktionVereinigte Staaten
-
Assiut UniversityNoch keine RekrutierungSepsis-induzierte Myokarddysfunktion | Sepsis induzierte KardiomyopathieÄgypten
-
University of Kansas Medical CenterUniversity of KansasRekrutierungSepsis | Septischer Schock | Sepsis-Syndrom | Sepsis, schwer | Bakterielle Sepsis | Sepsis-BakterämieVereinigte Staaten
-
Jip GroenInBiomeRekrutierungMikrobielle Besiedlung | Neonatale Infektion | Neonatale Sepsis, früher Beginn | Mikrobielle Krankheit | Klinische Sepsis | Kultur-negative neonatale Sepsis | Neonatale Sepsis, später Beginn | Kulturpositive neonatale SepsisNiederlande
-
Karolinska InstitutetÖrebro University, SwedenAbgeschlossenSepsis | Sepsis-Syndrom | Sepsis, schwerSchweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnbekannt
-
Ohio State UniversityAbgeschlossenSepsis, schwere Sepsis und septischer SchockVereinigte Staaten
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityAnmeldung auf EinladungSchwere Sepsis | Schwere Sepsis ohne septischen SchockVereinigte Staaten
-
Indonesia UniversityAbgeschlossenSchwere Sepsis mit septischem Schock | Schwere Sepsis ohne septischen SchockIndonesien
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsAbgeschlossenSepsis | Septischer Schock | Schwere Sepsis | Sepsis-SyndromVereinigtes Königreich